A second request did not stop Amazon's One Medical deal

The record

Amazon agreed to acquire the primary-care company One Medical, operated by 1Life Healthcare, Inc., under a merger agreement dated 20 July 2022. 1Life Healthcare's own Form 8-K, filed 2 September 2022, discloses that the companies made their antitrust filings under the Hart-Scott-Rodino Act on 3 August 2022 and that both parties received a Second Request from the Federal Trade Commission that same day in September, a step that extends the federal waiting period until the parties substantially comply with the request. The deal closed roughly five months later: a further Form 8-K, filed 22 February 2023, states that the merger became effective that day and that each share of One Medical common stock converted into the right to receive $18.00 in cash, with a related supplemental indenture fixing the same $18.00 figure into the conversion terms of the company's outstanding convertible notes.

What the documents establish

These are One Medical's own SEC disclosures, not Amazon's public statements or an FTC press release, and they document two distinct facts: that a Second Request was issued, and that the deal nonetheless closed roughly five months later without a public FTC enforcement action interrupting it. Neither filing states the FTC's reasoning for not seeking to block the deal, and none is cited here; the record shows only the sequence of a heightened antitrust review followed by an unblocked closing, not the agency's internal analysis. The February 2023 filing also confirms Amazon had provided One Medical an interim loan facility before closing, terminated at the Effective Time, a detail that shows financial support flowing before the deal formally closed.

The operating read

Editorially, a Second Request is a meaningful regulatory signal, but by itself it is not evidence that a deal is doomed; it is a standard escalation step whose outcome depends on what the parties substantially comply with next. Founders and boards evaluating an acquirer's own antitrust risk should look for the actual closing filing, not the Second Request announcement, before treating a deal as either blocked or cleared.

What to check before you decide

Before assuming a merger's regulatory story is finished, check what a target company's own filings actually confirm.

• Did a Second Request lead to a public enforcement action, a settlement, or simply an unremarked closing once compliance was complete?
• Does the closing 8-K state the actual per-share consideration, rather than relying on an earlier announcement's headline price?
• Were any interim financing arrangements between acquirer and target disclosed before closing, and were they properly unwound at the Effective Time?

1Life Healthcare's own filings, read together, show a five-month gap between a heightened antitrust review and an unchallenged close, which is the full extent of what the company's own record establishes about the FTC's role in this deal.